174 related articles for article (PubMed ID: 34433708)
21. [Utility and evaluation of immunohistochemical detection of BRAF V600E mutation in melanoma].
Lyu JJ; Kong YY; Cai X; Shen XX; Lu YW; Ren M
Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):548-552. PubMed ID: 28810295
[No Abstract] [Full Text] [Related]
22. Immunohistochemistry with a mutation-specific monoclonal antibody as a screening tool for the BRAFV600E mutational status in primary cutaneous malignant melanoma.
Feller JK; Yang S; Mahalingam M
Mod Pathol; 2013 Mar; 26(3):414-20. PubMed ID: 23041829
[TBL] [Abstract][Full Text] [Related]
23. Frequency of BRAF V600E mutations in 969 central nervous system neoplasms.
Behling F; Barrantes-Freer A; Skardelly M; Nieser M; Christians A; Stockhammer F; Rohde V; Tatagiba M; Hartmann C; Stadelmann C; Schittenhelm J
Diagn Pathol; 2016 Jun; 11(1):55. PubMed ID: 27350555
[TBL] [Abstract][Full Text] [Related]
24. Metastatic Malignant Melanoma With Complete Loss of Differentiation Markers (Undifferentiated/Dedifferentiated Melanoma): Analysis of 14 Patients Emphasizing Phenotypic Plasticity and the Value of Molecular Testing as Surrogate Diagnostic Marker.
Agaimy A; Specht K; Stoehr R; Lorey T; Märkl B; Niedobitek G; Straub M; Hager T; Reis AC; Schilling B; Schneider-Stock R; Hartmann A; Mentzel T
Am J Surg Pathol; 2016 Feb; 40(2):181-91. PubMed ID: 26448190
[TBL] [Abstract][Full Text] [Related]
25. Negative reactions of BRAF mutation-specific immunohistochemistry to non-V600E mutations of BRAF.
Seto K; Haneda M; Masago K; Fujita S; Kato S; Sasaki E; Hosoda W; Murakami Y; Kuroda H; Horio Y; Hida T; Okubo K; Yatabe Y
Pathol Int; 2020 May; 70(5):253-261. PubMed ID: 31970865
[TBL] [Abstract][Full Text] [Related]
26. Quantitative analysis of the BRAF
Ashida A; Sakaizawa K; Mikoshiba A; Uhara H; Okuyama R
Int J Clin Oncol; 2016 Oct; 21(5):981-988. PubMed ID: 27041702
[TBL] [Abstract][Full Text] [Related]
27. A novel BRAF mutation in association with primary amelanotic melanoma with oral metastases.
Zalaudek I; Ciarrocchi A; Piana S; Argenziano G; Torricelli F; Sancisi V; Gandolfi G; Longo C; Moscarella E; Banzi C; Nicoli D
J Eur Acad Dermatol Venereol; 2015 Feb; 29(2):387-390. PubMed ID: 24393566
[TBL] [Abstract][Full Text] [Related]
28. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.
Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M
Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704
[TBL] [Abstract][Full Text] [Related]
29. Molecular platforms utilized to detect BRAF V600E mutation in melanoma.
Curry JL; Torres-Cabala CA; Tetzlaff MT; Bowman C; Prieto VG
Semin Cutan Med Surg; 2012 Dec; 31(4):267-73. PubMed ID: 23174497
[TBL] [Abstract][Full Text] [Related]
30. Lymph node metastases of melanoma: challenges for BRAF mutation detection.
Chen G; Dudley J; Tseng LH; Smith K; Gurda GT; Gocke CD; Eshleman JR; Lin MT
Hum Pathol; 2015 Jan; 46(1):113-9. PubMed ID: 25456393
[TBL] [Abstract][Full Text] [Related]
31. Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma.
Tetzlaff MT; Pattanaprichakul P; Wargo J; Fox PS; Patel KP; Estrella JS; Broaddus RR; Williams MD; Davies MA; Routbort MJ; Lazar AJ; Woodman SE; Hwu WJ; Gershenwald JE; Prieto VG; Torres-Cabala CA; Curry JL
Hum Pathol; 2015 Aug; 46(8):1101-10. PubMed ID: 26058727
[TBL] [Abstract][Full Text] [Related]
32. Identification of the BRAF V600E mutation in a patient with sclerosing pneumocytoma: A case report.
Jiang G; Zhang M; Tan Q; Lin S; Zeng Y; Liu C; Chen R; Zhou J
Lung Cancer; 2019 Nov; 137():52-55. PubMed ID: 31546071
[TBL] [Abstract][Full Text] [Related]
33. BRAF V600E Mutations Occur in a Subset of Glomus Tumors, and Are Associated With Malignant Histologic Characteristics.
Karamzadeh Dashti N; Bahrami A; Lee SJ; Jenkins SM; Rodriguez FJ; Folpe AL; Boland JM
Am J Surg Pathol; 2017 Nov; 41(11):1532-1541. PubMed ID: 28834810
[TBL] [Abstract][Full Text] [Related]
34. Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?
Schirosi L; Strippoli S; Gaudio F; Graziano G; Popescu O; Guida M; Simone G; Mangia A
BMC Cancer; 2016 Nov; 16(1):905. PubMed ID: 27863476
[TBL] [Abstract][Full Text] [Related]
35. Molecular and immunohistochemical analysis of BRAF gene in primary cutaneous melanoma: Discovery of novel mutations.
Fatnassi-Mersni G; Arfaoui AT; Cherni M; Jones M; Zeglaoui F; Ouzari HI; Rammeh S
J Cutan Pathol; 2020 Sep; 47(9):794-799. PubMed ID: 32285462
[TBL] [Abstract][Full Text] [Related]
36. USE OF CIRCULATING TUMOR DNA FOR DETECTION OF BRAF V600E MUTATION AND TREATMENT MONITORING IN MELANOMA PATIENTS.
Shapochka D; Shapochka T; Seleznyov O; Matveeva A; Dudin V
Georgian Med News; 2018 Mar; (276):76-81. PubMed ID: 29697386
[TBL] [Abstract][Full Text] [Related]
37. Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation.
Ulivieri A; Cardillo G; Manente L; Paone G; Mancuso AP; Vigna L; Di Stasio E; Gasbarra R; Girlando S; Leone A
Oncotarget; 2015 Aug; 6(23):19868-79. PubMed ID: 26305188
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathological relevance of BRAF mutations in human cancer.
Pakneshan S; Salajegheh A; Smith RA; Lam AK
Pathology; 2013 Jun; 45(4):346-56. PubMed ID: 23594689
[TBL] [Abstract][Full Text] [Related]
39. Molecular characterization of novel melanoma cell lines.
Zanna P; Maida I; Turpin Sevilla MC; Susca FC; Filotico R; Arciuli M; Cassano N; Vena GA; Cicero R; Guida G
J Biol Regul Homeost Agents; 2011; 25(2):239-47. PubMed ID: 21880213
[TBL] [Abstract][Full Text] [Related]
40. [BRAF mutation evolution in melanoma: Myth or reality?].
Molines E; Haffner A; Fina F; Malissen N; Ouafik L; Grob JJ; Macagno N
Ann Pathol; 2022 Mar; 42(2):113-118. PubMed ID: 34865880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]